People exposed to proton‐pump inhibitors shortly preceding COVID‐19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: A nationwide matched cohort study
Ivan Kodvanj, Jan Homolak, Vladimir Trkulja
British Journal of Clinical Pharmacology, doi:10.1111/bcp.15525
Aims: To assess whether exposure to proton-pump inhibitors (PPIs) shortly preceding COVID-19 diagnosis affected the risk of subsequent hospitalizations and mortality.
Methods : This population-based study embraced first COVID-19 episodes in adults diagnosed up to 15 August 2021 in Croatia. Patients were classified based on exposure to PPIs and burden of PPI-requiring morbidities as nonusers (no issued prescriptions, no recorded treatment-requiring conditions between 1 January 2019 and COVID-19 diagnosis), possible users (no issued prescriptions, but morbidities present; self-medication possible) and users (≥1 prescription within 3 months prior to the COVID-19 diagnosis; morbidities present). Subsets were mutually exactly matched for pre-COVID-19 characteristics. The contrast between users and possible users informed about the effect of PPIs that is separate of the effect of PPI-requiring conditions. Results: Among 433 609 patients, users and possible users were matched 41 195 (of 55 098) to 17 334 (of 18 170) in the primary and 33 272 to 16 434 in the sensitivity analysis. There was no relevant difference between them regarding mortality (primary: relative risk [RR] = 0.93 [95% confidence interval 0.85-1.02; absolute risk difference [RD] = À0.34% [À0.73, 0.03]; sensitivity: RR = 0.88 [0.78-0.98]; RD = À0.45% [À0.80, À0.11]) or hospitalizations (primary: RR = 1.04 [0.97-1.13]; RD = 0.29% [À0.16, 0.73]; sensitivity: RR = 1.05 [0.97-1.15]; RD = 0.32% [À0.12, 0.75]). The risks of both were slightly higher in possible users or users than in nonusers (absolutely by $0.4-1.6%) indicating the effect of PPI-requiring morbidities. Conclusion: Premorbid exposure to PPIs does not affect the risk of death or hospitalization in adult COVID-19 patients, but PPI-requiring morbidities seemingly slightly increase the risk of both.
References
Freedberg, Kim, Yang, The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association, Gastroenterology,
doi:info:doi/10.1053/j.gastro.2017.01.031
Haastrup, Thompson, Søndergaard, Jarbøl, Side effects of long-term proton pump inhibitor use: a review, Basic Clin Pharmacol Toxicol,
doi:info:doi/10.1111/bcpt.13023
Israelsen, Ernst, Lundh, Proton pump inhibitor use is not strongly associated with SARS-CoV-2 related outcomes: a nationwide study and meta-analysis, Clin Gastroenterol Hepatol,
doi:info:doi/10.1016/j.cgh.2021.05.011
Kim, Kim, Wolf, Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis, Eur J Clin Pharmacol,
doi:info:doi/10.1007/s00228-021-03255-1
Lee, Ha, Yeniova, Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching, Gut,
doi:info:doi/10.1136/gutjnl-2020-322248
Salvo, Ferko, Cash, Gonzalez, Kahrilas, Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors, Aliment Pharmacol Ther,
doi:info:doi/10.1111/apt.16407
Yan, Chen, Sun, Does proton pump inhibitor use lead to a higher risk of coronavirus disease 2019 infection and progression to severe disease? A meta-analysis, Jpn J Infect Dis,
doi:info:doi/10.7883/yoken.JJID.2021.074
{ 'indexed': {'date-parts': [[2024, 5, 1]], 'date-time': '2024-05-01T00:54:19Z', 'timestamp': 1714524859024},
'reference-count': 36,
'publisher': 'Wiley',
'issue': '2',
'license': [ { 'start': { 'date-parts': [[2022, 10, 5]],
'date-time': '2022-10-05T00:00:00Z',
'timestamp': 1664928000000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}],
'funder': [ { 'DOI': '10.13039/501100007682',
'name': 'Medicinski Fakultet, Sveučilište u Zagrebu',
'doi-asserted-by': 'publisher'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2023, 2]]},
'abstract': '<jats:sec><jats:title>Aims</jats:title><jats:p>To assess whether exposure to proton‐pump '
'inhibitors (PPIs) shortly preceding COVID‐19 diagnosis affected the risk of subsequent '
'hospitalizations and '
'mortality.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This '
'population‐based study embraced first COVID‐19 episodes in adults diagnosed up to 15 August '
'2021 in Croatia. Patients were classified based on exposure to PPIs and burden of '
'PPI‐requiring morbidities as <jats:italic>nonusers</jats:italic> (no issued prescriptions, no '
'recorded treatment‐requiring conditions between 1 January 2019 and COVID‐19 diagnosis), '
'<jats:italic>possible users</jats:italic> (no issued prescriptions, but morbidities present; '
'self‐medication possible) and <jats:italic>users</jats:italic> (≥1 prescription within 3\xa0'
'months prior to the COVID‐19 diagnosis; morbidities present). Subsets were mutually exactly '
'matched for pre‐COVID‐19 characteristics. The contrast between '
'<jats:italic>users</jats:italic> and <jats:italic>possible users</jats:italic> informed about '
'the effect of PPIs that is separate of the effect of PPI‐requiring '
'conditions.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among '
'433\u2009609 patients, <jats:italic>users</jats:italic> and <jats:italic>possible '
'users</jats:italic> were matched 41\u2009195 (of 55\u2009098) to 17\u2009334 (of 18\u2009170) '
'in the primary and 33\u2009272 to 16\u2009434 in the sensitivity analysis. There was no '
'relevant difference between them regarding mortality (primary: relative risk [RR]\u2009=\xa0'
'0.93 [95% confidence interval 0.85–1.02; absolute risk difference [RD]\u2009=\u2009−0.34% '
'[−0.73, 0.03]; sensitivity: RR\u2009=\xa00.88 [0.78–0.98]; RD\u2009=\u2009−0.45% [−0.80, '
'−0.11]) or hospitalizations (primary: RR\u2009=\xa01.04 [0.97–1.13]; RD\u2009=\xa00.29% '
'[−0.16, 0.73]; sensitivity: RR\u2009=\xa01.05 [0.97–1.15]; RD\u2009=\xa00.32% [−0.12, 0.75]). '
'The risks of both were slightly higher in <jats:italic>possible users</jats:italic> or '
'<jats:italic>users</jats:italic> than in <jats:italic>nonusers</jats:italic> (absolutely by '
'~0.4–1.6%) indicating the effect of PPI‐requiring '
'morbidities.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Premorbid '
'exposure to PPIs does not affect the risk of death or hospitalization in adult COVID‐19 '
'patients, but PPI‐requiring morbidities seemingly slightly increase the risk of '
'both.</jats:p></jats:sec>',
'DOI': '10.1111/bcp.15525',
'type': 'journal-article',
'created': {'date-parts': [[2022, 9, 12]], 'date-time': '2022-09-12T14:09:31Z', 'timestamp': 1662991771000},
'page': '787-831',
'source': 'Crossref',
'is-referenced-by-count': 1,
'title': 'People exposed to proton‐pump inhibitors shortly preceding COVID‐19 diagnosis are not at an '
'increased risk of subsequent hospitalizations and mortality: A nationwide matched cohort study',
'prefix': '10.1111',
'volume': '89',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-1359-3701',
'authenticated-orcid': False,
'given': 'Ivan',
'family': 'Kodvanj',
'sequence': 'first',
'affiliation': [ { 'name': 'Department of Gastroenterology and Hepatology University '
'Hospital Center Zagreb Zagreb Croatia'}]},
{ 'given': 'Jan',
'family': 'Homolak',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology Zagreb University School of Medicine '
'Zagreb Croatia'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-0968-1194',
'authenticated-orcid': False,
'given': 'Vladimir',
'family': 'Trkulja',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology Zagreb University School of Medicine '
'Zagreb Croatia'}]}],
'member': '311',
'published-online': {'date-parts': [[2022, 10, 5]]},
'reference': [ { 'key': 'e_1_2_10_2_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1097/MOG.0000000000000676'},
{ 'key': 'e_1_2_10_3_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1053/j.gastro.2017.01.031'},
{ 'key': 'e_1_2_10_4_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.jamda.2020.09.046'},
{ 'key': 'e_1_2_10_5_1',
'unstructured': 'Association of the European Self‐Care Industry.AESGP OTC ingredients '
'directory.https://aesgp.eu/databases'},
{'key': 'e_1_2_10_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/bcpt.13023'},
{'key': 'e_1_2_10_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.12759'},
{'key': 'e_1_2_10_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/apt.16407'},
{'key': 'e_1_2_10_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40261‐020‐00963‐x'},
{ 'key': 'e_1_2_10_10_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s40261‐021‐01007‐8'},
{ 'key': 'e_1_2_10_11_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ijantimicag.2020.106044'},
{ 'key': 'e_1_2_10_12_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.mehy.2020.110018'},
{'key': 'e_1_2_10_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cgh.2021.05.011'},
{ 'key': 'e_1_2_10_14_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s43440‐021‐00263‐x'},
{ 'key': 'e_1_2_10_15_1',
'doi-asserted-by': 'publisher',
'DOI': '10.7883/yoken.JJID.2021.074'},
{ 'key': 'e_1_2_10_16_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s00228‐021‐03255‐1'},
{ 'key': 'e_1_2_10_17_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41467‐020‐19478‐2'},
{ 'key': 'e_1_2_10_18_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1053/j.gastro.2020.09.028'},
{ 'key': 'e_1_2_10_19_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/gutjnl‐2020‐322248'},
{ 'key': 'e_1_2_10_20_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/gutjnl‐2020‐323672'},
{'key': 'e_1_2_10_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1017/pan.2019.11'},
{ 'key': 'e_1_2_10_22_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1053/j.gastro.2017.07.045'},
{ 'key': 'e_1_2_10_23_1',
'unstructured': 'Medicinal products database. Agency for Medicinal Products and Medical '
'Devices of '
'Croatia.https://www.halmed.hr/Lijekovi/Baza-lijekova/#rezultati'},
{'key': 'e_1_2_10_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.18637/jss.v042.i08'},
{ 'key': 'e_1_2_10_25_1',
'unstructured': 'R Core Team.R: a language and environment for statistical computing. R '
'Foundation for Statistical Computing Vienna Austria;2020.'},
{'key': 'e_1_2_10_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/M16‐2607'},
{ 'key': 'e_1_2_10_27_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/ebmental‐2019‐300117'},
{ 'key': 'e_1_2_10_28_1',
'first-page': 'S297',
'article-title': 'The concise guide to pharmacology 2019/20: enzymes',
'volume': '176',
'author': 'Alexander SPH',
'year': '2019',
'journal-title': 'Br J Pharmacol'},
{ 'key': 'e_1_2_10_29_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1177/003591576505800503'},
{ 'key': 'e_1_2_10_30_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s10654‐019‐00494‐6'},
{'key': 'e_1_2_10_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/aje/kwr352'},
{ 'key': 'e_1_2_10_32_1',
'first-page': '417',
'volume-title': 'Proceedings of UAI',
'author': 'Pearl J',
'year': '2010'},
{'key': 'e_1_2_10_33_1', 'doi-asserted-by': 'publisher', 'DOI': '10.5056/jnm21095'},
{ 'key': 'e_1_2_10_34_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pone.0264704'},
{ 'key': 'e_1_2_10_35_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1186/s12879‐022‐07262‐0'},
{ 'key': 'e_1_2_10_36_1',
'unstructured': 'Croatia: coronavirus pandemic country profile. Our World in Data '
'(Accessed July 2 2022).'},
{ 'key': 'e_1_2_10_37_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1097/01.mlr.0000182534.19832.83'}],
'container-title': 'British Journal of Clinical Pharmacology',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15525',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bcp.15525',
'content-type': 'application/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15525',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 8, 20]],
'date-time': '2023-08-20T08:43:38Z',
'timestamp': 1692521018000},
'score': 1,
'resource': {'primary': {'URL': 'https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15525'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 10, 5]]},
'references-count': 36,
'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2023, 2]]}},
'alternative-id': ['10.1111/bcp.15525'],
'URL': 'http://dx.doi.org/10.1111/bcp.15525',
'relation': { 'has-preprint': [ { 'id-type': 'doi',
'id': '10.1101/2022.04.30.22274526',
'asserted-by': 'object'}]},
'ISSN': ['0306-5251', '1365-2125'],
'subject': [],
'container-title-short': 'Brit J Clinical Pharma',
'published': {'date-parts': [[2022, 10, 5]]}}